10-Q Filing

GUIDED THERAPEUTICS INC CIK: 924515 Q1 2012

Filing Information

Form Type	10-Q
Accession Number	`0001121781-12-000160`
Period End Date	20120331
Filing Date	20120514
Fiscal Year	2012
Fiscal Period	Q1
XBRL Instance	gthp-20120331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 68 Income Statement 26 Cash Flow Statement 58

Balance Sheet 68 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$20.00K	USD	Point-in-time
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$4.00K	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$64.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.27M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.31M	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$64.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.00M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $4 and $20 at March 31, 2012 and December 31, 2011	`AccountsReceivableNet`	$38.00K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $4 and $20 at March 31, 2012 and December 31, 2011	`AccountsReceivableNet`	$117.00K	USD	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	100,000.00	shares	Point-in-time
Inventory, net of reserves of $64 at March 31, 2012 and December 31, 2011	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$520.00K	USD	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	100,000.00	shares	Point-in-time
Inventory, net of reserves of $64 at March 31, 2012 and December 31, 2011	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$608.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$54.00K	USD	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	52,211.00	shares	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	52,697.00	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$45.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.70M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$2.89M	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	52,697.00	shares	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	52,211.00	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.03M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.09M	USD	Point-in-time
Other Assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$386.00K	USD	Point-in-time
Other Assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$302.00K	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$1.39M	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$1.42M	USD	Point-in-time
Total assets	`Assets`	$4.31M	USD	Point-in-time
Total assets	`Assets`	$3.08M	USD	Point-in-time
Short-term notes payable	`ShorttermNotesPayable`	$30.00K	USD	Point-in-time
Short-term notes payable	`ShorttermNotesPayable`	-	USD	Point-in-time
Current portion of long-term debt	`ShortTermBorrowings`	$25.00K	USD	Point-in-time
Current portion of long-term debt	`ShortTermBorrowings`	$24.00K	USD	Point-in-time
Notes payable - past due	`NotesPayablePastDue`	$375.00K	USD	Point-in-time
Notes payable - past due	`NotesPayablePastDue`	$362.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$863.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.10M	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$757.00K	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$687.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$228.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$453.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.18M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.73M	USD	Point-in-time
Long-term debt payable, less current portion	`LongTermDebt`	-	USD	Point-in-time
Long-term debt payable, less current portion	`LongTermDebt`	$4.00K	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.73M	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.18M	USD	Point-in-time
COMMITMENTS & CONTINGENCIES (Note 4)	`CommitmentsAndContingencies`	-	USD	Point-in-time
COMMITMENTS & CONTINGENCIES (Note 4)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $.001 Par value; 100,000 shares authorized, 52,697 and 52,211 shares issued and outstanding as of March, 31 2012 and December 31, 2011, respectively	`CommonStockValue`	$53.00K	USD	Point-in-time
Common stock, $.001 Par value; 100,000 shares authorized, 52,697 and 52,211 shares issued and outstanding as of March, 31 2012 and December 31, 2011, respectively	`CommonStockValue`	$52.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$86.61M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$86.96M	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$104.00K	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$104.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-86.10M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-85.09M	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	`TotalGuidedTherapeuticsStockholdersEquity`	$804.00K	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	`TotalGuidedTherapeuticsStockholdersEquity`	$1.47M	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$104.00K	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$104.00K	USD	Point-in-time
TOTAL STOCKHOLDERS' EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.58M	USD	Point-in-time
TOTAL STOCKHOLDERS' EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$908.00K	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$3.08M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$4.31M	USD	Point-in-time

Income Statement 26 line items

Line Item	Tag	Value	Unit	Period
Contract and grant revenue	`Revenues`	$767.00K	USD	1 Quarter
Contract and grant revenue	`Revenues`	$718.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$696.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$714.00K	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$49.00K	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$70.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$762.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$930.00K	USD	1 Quarter
Total	`CostsAndExpenses`	$1.51M	USD	1 Quarter
Total	`CostsAndExpenses`	$1.71M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-740.00K	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-996.00K	USD	1 Quarter
OTHER INCOME	`OtherIncome`	-	USD	1 Quarter
OTHER INCOME	`OtherIncome`	$37.00K	USD	1 Quarter
INTEREST EXPENSE	`InterestExpense`	$17.00K	USD	1 Quarter
INTEREST EXPENSE	`InterestExpense`	$23.00K	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`LossBeforeIncomeTaxes`	$726.00K	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`LossBeforeIncomeTaxes`	$1.01M	USD	1 Quarter
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	1 Quarter
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-726.00K	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-1.01M	USD	1 Quarter
BASIC AND DILUTED NET LOSS PER SHARE	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
BASIC AND DILUTED NET LOSS PER SHARE	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	52,471.00	shares	1 Quarter
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	47,851.00	shares	1 Quarter

Cash Flow Statement 58 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-726.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.01M	USD	1 Quarter
Bad debt recovery	`BadDebtRecovery`	-	USD	1 Quarter
Bad debt recovery	`BadDebtRecovery`	$-16.00K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$4.00K	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$75.00K	USD	1 Quarter
Stock based compensation	`ShareBasedCompensation`	$142.00K	USD	1 Quarter
Stock based compensation	`ShareBasedCompensation`	$198.00K	USD	1 Quarter
Conversion of interest to principal	`ConversionOfInterestToPrincipal`	-	USD	1 Quarter
Conversion of interest to principal	`ConversionOfInterestToPrincipal`	$23.00K	USD	1 Quarter
Gain on debt renegotiated	`GainOnDebtRenigotiated`	-	USD	1 Quarter
Gain on debt renegotiated	`GainOnDebtRenigotiated`	$-23.00K	USD	1 Quarter
Inventory	`IncreaseDecreaseInInventories`	$-88.00K	USD	1 Quarter
Inventory	`IncreaseDecreaseInInventories`	-	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-58.00K	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$96.00K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$8.00K	USD	1 Quarter
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$6.00K	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-239.00K	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$36.00K	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-225.00K	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-253.00K	USD	1 Quarter
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-108.00K	USD	1 Quarter
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-70.00K	USD	1 Quarter
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$84.00K	USD	1 Quarter
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-62.00K	USD	1 Quarter
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$-177.00K	USD	1 Quarter
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$-293.00K	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-1.02M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-1.19M	USD	1 Quarter
Additions to capitalized software costs	`CapitalizedComputerSoftwareAdditions`	-	USD	1 Quarter
Additions to capitalized software costs	`CapitalizedComputerSoftwareAdditions`	$-53.00K	USD	1 Quarter
Additions to fixed assets	`AdditionsToNoncurrentAssets`	$-16.00K	USD	1 Quarter
Additions to fixed assets	`AdditionsToNoncurrentAssets`	$-130.00K	USD	1 Quarter
Net cash (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-130.00K	USD	1 Quarter
Net cash (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-69.00K	USD	1 Quarter
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$175.00K	USD	1 Quarter
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$146.00K	USD	1 Quarter
Payments made on notes payable	`PaymentsOfLoanCosts`	$48.00K	USD	1 Quarter
Payments made on notes payable	`PaymentsOfLoanCosts`	$22.00K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$127.00K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$124.00K	USD	1 Quarter
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-961.00K	USD	1 Quarter
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-1.20M	USD	1 Quarter
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$3.27M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$2.31M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$1.00M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$3.27M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.31M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$1.00M	USD	Point-in-time
Cash paid for Interest	`InterestPaid`	$5.00K	USD	1 Quarter
Cash paid for Interest	`InterestPaid`	$1.00K	USD	1 Quarter
Conversion of accounts payable into common stock	`ConversionOfAccountsPayableIntoCommonStock`	-	USD	1 Quarter
Conversion of accounts payable into common stock	`ConversionOfAccountsPayableIntoCommonStock`	$27.00K	USD	1 Quarter
Settlement of debt upon conversion of warrants	`SettlementOfDebtUponConversionOfWarrants`	$42.00K	USD	1 Quarter
Settlement of debt upon conversion of warrants	`SettlementOfDebtUponConversionOfWarrants`	-	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.